Search results for "68Ga"

showing 10 items of 14 documents

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

2020

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study is to determine the optimum time for performing these PET/CT scans in a large cohort of patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve (ROC) generated by plottin…

Biochemical recurrenceCancer Researchmedicine.medical_treatment68Gallium-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine<sup>68</sup>gallium-psma pet/ctprostate-specific-antigenPSA kinetics thresholdsbiochemical recurrenceMedicineoptimal cutoff levelPET-CTPsa kineticsbusiness.industryProstatectomylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensprostate cancermedicine.diseaseRadiation therapyProstate-specific antigenOncology030220 oncology & carcinogenesisRecurrent prostate cancerbusinessNuclear medicineCancers
researchProduct

Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of …

2020

Gallium-68 (Ga) prostate-specific-membrane-antigen positron-emission-tomography/computed-tomography is a highly promising method for imaging primary and recurrent prostate cancer. These dual-modality imaging technologies enable whole-body functional and anatomical evaluation in a single session. This study investigated the performance of Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with Ga-prostate-specific-membrane-antig…

Biochemical recurrenceMalemedicine.medical_specialtyEpidemiologyHealth Toxicology and MutagenesisGallium RadioisotopesRisk Assessment68Ga-PSMA-11Cohort StudiesProstate cancerPositron Emission Tomography Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingRadiation treatment planningPathologicalEdetic AcidGallium IsotopesPositron Emission Tomography-Computed TomographyNeoplasm StagingRetrospective Studiesbusiness.industryProstatic NeoplasmsProstate carcinomamedicine.diseaseLarge cohortTreatment OutcomeGene Expression RegulationLymphatic MetastasisRadiologyNeoplasm Recurrence LocalbusinessOligopeptidesHealth physics
researchProduct

Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOC.

2008

Abstract Introduction Imaging of somatostatin receptor expressing tumours has been greatly enhanced by the use of 68 Ga-DOTATOC and PET/CT. Methods In this work, a purification method for the 68 Ge/ 68 Ga generator eluate and a method to produce 68 Ga-DOTATOC suitable for clinical use were evaluated. The generator eluate was purified and concentrated on a cation-exchange cartridge in HCl/acetone media. The efficacy of this procedure in eliminating metal impurities from the 68 Ga solution was investigated by ICP-MS. The radiotracer quality was evaluated by radio-TLC, GC and γ-ray spectrometry. Results 68 Ga-DOTATOC preparations ( n =33) were carried out with a mean synthesis yield of 59.3±2.…

Cancer ResearchGenerator (computer programming)ChromatographyElutionIon chromatographyGallium RadioisotopesMass spectrometryOctreotide68ga dotatocchemistry.chemical_compoundchemistryYield (chemistry)Isotope LabelingPositron-Emission TomographyAcetoneOrganometallic CompoundsMolecular MedicineRadiology Nuclear Medicine and imagingPurification methodsClinical MedicineRadiopharmaceuticalsNuclear medicine and biology
researchProduct

An unusual case of chronic diarrhea: a case report

2022

Gastroenteropancreatic-neuroendocrine neoplasms or tumors (GEP-NEN or NETs) are rare tumors arising from the diffuse neuroendocrine system. This clinical case highlights the complexity of the diagnostic process and the difficulties in interpreting the examinations for this type of tumor, showing how the negativity of firstlevel examinations did not prevent from performing further investigations, in the presence of a suggestive clinical presentation. The search of similar cases in the published literature suggests that this represents an unusual presentation of a NET.

DiarrheaSettore MED/09 - Medicina InternaPositron-Emission TomographyPositron Emission Tomography Computed TomographyEmergency MedicineInternal MedicineHumansOctreotide68Gallium-DOTATOC PET/CT Chromogranin A Diarrhea Gastroenteropancreatic-neuroendocrine tumor
researchProduct

The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.

2018

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an exce…

MaleUrology030232 urology & nephrologyComputed tomographyGallium Radioisotopesurologic and male genital diseasesMultimodal ImagingManagement of prostate cancer03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographymedicineOrganometallic CompoundsHumansGallium IsotopesMembrane antigenSalvage TherapyPET-CTMembrane Glycoproteinsmedicine.diagnostic_testbusiness.industry68ga psmaProstatic NeoplasmsMagnetic resonance imagingProstate carcinomaProstate-Specific AntigenMagnetic Resonance ImagingPositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyNeoplasm Recurrence LocalRadiopharmaceuticalsbusinessNuclear medicineUrology
researchProduct

Reply: “The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer”

2019

PET-CTmedicine.diagnostic_testbusiness.industryUrology68ga psmaMagnetic resonance imagingPet imagingManagement of prostate cancerPositron emission tomographymedicineHaloNuclear medicinebusinessScatter correctionUrology
researchProduct

Gallija-68 [68Ga] un fluora-18 [18F] izotopu iegūšana un izmantošana radiofarmaceitisko preparātu sintēzē

2017

Gallija-68 [68Ga] un fluora-18 [18F] izotopu iegūšana un izmantošana radiofarmaceitisko preparātu sintēzē. Mamis E., zinātniskais vadītājs Prof. Dr.h.c. Chem Andris Actiņš, zinātniskie konsultanti Mg. Chem Jāzeps Malnačs un Mg. Med. Phys., Dipl. Ing., Mg. Sc. Ing Linda Meistere. Maģistra darbs, 54 lappuses, 28 attēli, 12 tabulas, 20 literatūras avoti. Latviešu valodā. Darbā ir apkopota literatūra par radionuklīdu iegūšanas procesiem kodolreakcijas ceļā, izmantojot daļiņu paātrinātāju – ciklotronu un 68Ge/68Ga ģeneratoru, sintēzes procesiem noteiktu radiofarmaceitisko preparātu iegūšanā, kā arī pozitronu emisijas tomogrāfijas tehnoloģiju un tās izmantošanas iespējas onkoloģisko saslimšanu di…

POZITRONU EMISIJAS TOMOGRĀFIJA68Ge/68Ga ĢENERATORSCIKLOTRONS[68Ga] RADIONUKLĪDSĶīmija[18F] RADIONUKLĪDS
researchProduct

In vitro vēža šūnu modeļsistēmas izstrāde molekulāri mērķētu radionuklīdu testēšanai

2019

Prostatas vēzis ir ceturtais biežāk diagnosticētais vēzis Eiropā, 2018. gadā un tas ir kļuvis par visbiežāk sastopamo vēzi vīriešu vidū. Nozīmīgi klīnisko pētījumu rezultāti prostatas vēža diagnostikā un terapijā ir sasniegti ar radioaktīvi iezīmētu PSMA ligandu 68Ga-PSMA – diagnostikai un 177Lu-PSMA – terapijai. Neiroendokrīnie audzēji ir neviendabīga agresīvu audzēju grupa, kam raksturīgi dažādi un bieži nespecifiski simptomi, kas apgrūtina precīzu audzēja primāro diagnostiku un saslimšanas stadijas precizēšanu. Pašlaik šo audzēju diagnostikā un ārstēšanā izmanto ar SSTR2 ligandiem (somatostatīna analogiem) konjugētus radionuklīdus. Šī darba mērķis bija izveidot uz dažādām šūnu līnijām ba…

Prostatas vēzisSSTR2 un PSMAin vitro modeļsistēmaBioloģija68Ga un 177Lu radionuklīdineiroendokrīnais vēzis
researchProduct

Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.

2017

Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are characterized by an increased bone turnover, which can be visualized by positron emission tomography (PET), as well as single-photon emission computed tomography (SPECT). Bisphosphonate complexes of 99mTc are predominantly used as SPECT tracers. In contrast to SPECT, PET offers a higher spatial resolution and, owing to the 68Ge/68Ga generator, an analog to the established 99mTc generator exists. Complexation of Ga(III) requires the use of chelators. Therefore, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), and their derivatives, are ofte…

diagnosismedicine.medical_treatmentPharmaceutical ScienceReview030218 nuclear medicine & medical imagingBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebone metastasesDrug DiscoverymedicineDOTAbisphosphonatestherapymedicine.diagnostic_testbusiness.industryBisphosphonate177Lu68GachemistryPositron emission tomography030220 oncology & carcinogenesisMolecular MedicineNuclear medicinebusinessEmission computed tomographyPharmaceuticals (Basel, Switzerland)
researchProduct

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

2021

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.

endocrine systemQH301-705.5CellMedicine (miscellaneous)ReviewGeneral Biochemistry Genetics and Molecular BiologymedicineBiology (General)Tumorspeptide receptor radionuclide therapyReceptors d'hormonesneuroendocrine neoplasmssomatostatin analoguesSomatostatin receptorbusiness.industryTreatment optionsLU-DOTA-TATEmedicine.anatomical_structureSomatostatinPotential biomarkerssomatostatin receptorssomatostatin antagonistsCancer research68Ga PETbusinesshormones hormone substitutes and hormone antagonistsBiomedicines
researchProduct